

SEPTEMBER 2022 QUARTERLY UPDATE

- **Bio-Gene/commercial partners programs advancing through development**
- **Advancement of other commercial programs with new potential commercial partners**
- **Regulatory authorities in key markets now engaged on registration pathways with potential for early submissions**
- **Manufacturing improvements leading to assurance on commercial manufacturing viability**
- **Patent application submitted in Australia for Qcide™ use for winged insect control**

Bio-Gene Technology Limited (ASX: BGT, 'Bio-Gene' or 'the Company'), an agtech development company enabling the next generation of novel insecticides, today announced an update on its activities for the quarter ending 30 September 2022 and to date.

Bio-Gene Chief Executive Officer and Managing Director, Richard Jagger said: "The September quarter has seen some significant work undertaken that will enable us to further deliver on our strategy over the coming months. This positive progress falls into three major categories:

- 1) commercial development;
- 2) regulatory development; and
- 3) manufacturing development."

Commercial Development

The Company has been progressing its commercial product development with our existing partners as we collaboratively work towards opportunities in the mosquito and consumer space. In addition, Bio-Gene has been working closely with several other companies to explore areas of potential interest. This has involved numerous meetings and data sharing as we pinpoint specific market opportunities that are relevant to those companies and are of value to Bio-Gene. Our aim is to progress these discussions into more commercial oriented agreements similar to those with our existing partners, that will lead to product development and the creation of end use products. This is in line with our strategy of identifying multiple revenue streams through different market applications of our products.

Regulatory Development

A very important part of commercialising our technology is obtaining regulatory approval in various geographies. This process requires some finesse, as different markets and different jurisdictions require a different regulatory package. Our aim has been to clearly identify and prioritise the data requirements for our target segments and continue the process of data generation. In some cases, this requires detailed protocols and bespoke testing, and we are fortunate to have regulatory experts to assist in developing and implementing strategy to optimise use of resources and minimise time to product approvals. Pleasingly, we are making progress with our toxicology studies, and continue to engage with the regulatory authorities in collaboration with our commercial partners.

Manufacturing Development

Flavocide™

We have been engaging with several specialist organisations both in Australia and overseas that has enabled us to focus on refinements to our Standard Operating Procedure for producing Flavocide. We are now confident that we have the pathway to produce commercially viable quantities of the product. In addition, we have shortlisted several toll manufacturers, and will be conducting face to face audits over the coming months to confirm their suitability. Ultimately the lead candidate will be contracted to begin the process of commercial manufacture of our product.

Qcide™

The focus with Qcide production has been across two major areas:

Firstly, we have continued to refine the process for oil extraction, which is based on a steam distillation system. This ensures we get the maximum amount of oil extracted from the biomass for the energy expelled in the process. Secondly, we have been phenotyping various trees in our plantation to identify individuals that have higher oil content in the biomass, as well as higher levels of Tasmanone (the active ingredient). As part of this program, we are poised to undertake a Plant Breeders Rights program which will help us protect the I.P. surrounding these superior trees.

Our next harvest is planned for early November 2022.

With a lot of specific activity focused on manufacturing in recent months, we are planning to conduct a webinar soon where Dr. Wade, our program manager, will explain the manufacturing strategy and related developments in detail. We will announce the details of this webinar soon.

Intellectual Property

As previously reported, in June 2022 Bio-Gene submitted a provisional patent application in Australia that relates to the use of Qcide and other β -diketones used in combination with a pyrethroid or pyrethrin compound for the control of winged insects. The patent application focuses on the control of mosquito and fly species, including resistant strains, with evidence supporting synergy of these combinations. Other patent applications relating to Qcide are under consideration. Our investment in strengthening and broadening our IP adds value to Bio-Gene and to our commercial partners.

Communications

We continue to build on our social media interactions with regular communications on company activities and global issues relevant to our business development activities. These and on-going updates can be found on our social media pages:

- LinkedIn: - <https://au.linkedin.com/company/bio-genetechnology>
- Twitter: - <https://twitter.com/biogenetechltd>

The Company will continue to focus on investor briefings and industry presentations over the course of the year.

Cash Position

As at 30 September 2022, Bio-Gene held \$5.3 million in cash, which based on current plans, provides the Company with sufficient cash to operate beyond 12 months.

Approved for release by the Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger
Chief Executive Officer
P: 03 9068 1062
E: bgt.info@bio-gene.com.au

Roger McPherson
CFO & Company Secretary
P: 03 9068 1062
E: bgt.info@bio-gene.com.au

Media/investor relations:

Rudi Michelson
Monsoon Communications
P: 03 9620 3333
E: rudim@monsoon.com.au

About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g., kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, consumer applications and animal health. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions, working with industry leaders across key market segments.

Flavocide™ and Qcide™ are trademarks of Bio-Gene Technology Limited.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bio-Gene Technology Limited

ABN

32 071 735 950

Quarter ended ("current quarter")

30 September 2022

Consolidated statement of cash flows	Current quarter \$A'000	Year to date \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(585)	(585)
(b) commercialisation expenses	(171)	(171)
(c) management administration expenses	(94)	(94)
(d) directors' expenses	(82)	(82)
(e) professional services	(25)	(25)
(f) intellectual property	(87)	(87)
(g) administration and corporate costs (see note 6)	(53)	(53)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	21	21
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(1,076)	(1,076)

2.	Cash flows from investing activities	-	-
2.1	Payments to acquire or for:		
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:	-	-
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	0	0

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (share proceeds received in advance)	-	-
3.10	Net cash from / (used in) financing activities	0	0

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	6,342	6,342
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,076)	(1,076)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	5,266	5,266

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	19	36
5.2	Call deposits	5,247	6,306
5.3	Bank overdrafts	-	-
5.4	Other (Term Deposits)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,266	7,229

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	409
6.2	Aggregate amount of payments to related parties and their associates included in item 2	N/A
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Note 6.1: Director's fees paid to Directors or their related entities which includes FY22 incentives for Executive Directors.

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	N/A	N/A
7.2	Credit standby arrangements	N/A	N/A
7.3	Other (please specify)	N/A	N/A
7.4	Total financing facilities	N/A	N/A
7.5	Unused financing facilities available at quarter end		N/A
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	1,076
8.2	Cash and cash equivalents at quarter end (item 4.6)	5,266
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	5,266
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	5
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer:	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer:	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer:	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 October 2022

Authorised by: The Board of Directors
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
6. Net movements in GST are included in this item.
7. Prior Quarter Corrections. Immaterial minor errors and reallocations of expenses from previous quarter reports are corrected on a year to date basis. Movements disclosed for the current quarter have been correctly calculated.